Cardiac Spinal Afferent Denervation Attenuates Renal Dysfunction in Rats With Cardiorenal Syndrome Type 2
© 2022 The Authors..
Cardiorenal syndrome type 2 (CRS2) is defined as a chronic cardiovascular disease, usually chronic heart failure (CHF), resulting in chronic kidney disease. We hypothesized that the cardiac spinal afferent reflex (CSAR) plays a critical role in the development of CRS2. Our data suggest that cardiac afferent ablation by resiniferatoxin not only improves cardiac function but also benefits the kidneys and increases long-term survival in the myocardial infarction model of CHF. We also found that renal denervation has a similar reno-protective effect in CHF rats. We believe this novel work contributes to the development of a unique neuromodulation therapy to treat CHF patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:7 |
|---|---|
| Enthalten in: |
JACC. Basic to translational science - 7(2022), 6 vom: 15. Juni, Seite 582-596 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Xia, Zhiqiu [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Revised 16.07.2022 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.jacbts.2022.02.008 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM343389193 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM343389193 | ||
| 003 | DE-627 | ||
| 005 | 20231226020332.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jacbts.2022.02.008 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1144.xml |
| 035 | |a (DE-627)NLM343389193 | ||
| 035 | |a (NLM)35818505 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Xia, Zhiqiu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cardiac Spinal Afferent Denervation Attenuates Renal Dysfunction in Rats With Cardiorenal Syndrome Type 2 |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 16.07.2022 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2022 The Authors. | ||
| 520 | |a Cardiorenal syndrome type 2 (CRS2) is defined as a chronic cardiovascular disease, usually chronic heart failure (CHF), resulting in chronic kidney disease. We hypothesized that the cardiac spinal afferent reflex (CSAR) plays a critical role in the development of CRS2. Our data suggest that cardiac afferent ablation by resiniferatoxin not only improves cardiac function but also benefits the kidneys and increases long-term survival in the myocardial infarction model of CHF. We also found that renal denervation has a similar reno-protective effect in CHF rats. We believe this novel work contributes to the development of a unique neuromodulation therapy to treat CHF patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a BUN, blood urea nitrogen | |
| 650 | 4 | |a CHF, chronic heart failure | |
| 650 | 4 | |a CRS2, cardiorenal syndrome type 2 | |
| 650 | 4 | |a CSAR, cardiac spinal afferent reflex | |
| 650 | 4 | |a EF, ejection fraction | |
| 650 | 4 | |a FS, fractional shortening | |
| 650 | 4 | |a GFR, glomerular filtration rate | |
| 650 | 4 | |a HR, heart rate | |
| 650 | 4 | |a Kim-1, kidney injury molecule 1 | |
| 650 | 4 | |a MAP, mean arterial blood pressure | |
| 650 | 4 | |a MI, myocardial infarction | |
| 650 | 4 | |a Ngal, neutrophil gelatinase–associated lipocalin | |
| 650 | 4 | |a RBF, renal blood flow | |
| 650 | 4 | |a RTX, resiniferatoxin | |
| 650 | 4 | |a RVR, renal vascular resistance | |
| 650 | 4 | |a URDN, unilateral renal denervation | |
| 650 | 4 | |a cardiorenal syndrome type 2 | |
| 650 | 4 | |a cardiovascular reflexes | |
| 650 | 4 | |a chronic heart failure | |
| 650 | 4 | |a inflammation | |
| 650 | 4 | |a renal failure | |
| 650 | 4 | |a sympathoexcitation | |
| 700 | 1 | |a Vellichirammal, Neetha Nanoth |e verfasserin |4 aut | |
| 700 | 1 | |a Han, Li |e verfasserin |4 aut | |
| 700 | 1 | |a Gao, Lie |e verfasserin |4 aut | |
| 700 | 1 | |a Boesen, Erika I |e verfasserin |4 aut | |
| 700 | 1 | |a Schiller, Alicia M |e verfasserin |4 aut | |
| 700 | 1 | |a Pellegrino, Peter R |e verfasserin |4 aut | |
| 700 | 1 | |a Lisco, Steven J |e verfasserin |4 aut | |
| 700 | 1 | |a Guda, Chittibabu |e verfasserin |4 aut | |
| 700 | 1 | |a Zucker, Irving H |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Han-Jun |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t JACC. Basic to translational science |d 2016 |g 7(2022), 6 vom: 15. Juni, Seite 582-596 |w (DE-627)NLM258427175 |x 2452-302X |7 nnns |
| 773 | 1 | 8 | |g volume:7 |g year:2022 |g number:6 |g day:15 |g month:06 |g pages:582-596 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jacbts.2022.02.008 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 7 |j 2022 |e 6 |b 15 |c 06 |h 582-596 | ||